Contact Information: Contact: The Global Consulting Group Rachel Levine T: (646) 284-9439 E:
Cleveland BioLabs to Present at Roth Capital Partners 2007 New York Conference
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - August 28, 2007) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) (BOST : CBLI ) today announced that the Company is scheduled to present at the Roth
Capital Partners 2007 New York Conference, September 5-6, 2007, in New
York, NY.
Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland
BioLabs, will give a presentation on the Company, followed by a question
and answer session on September 6, at 2:00 p.m. ET. The presentation will
be broadcast live over the Internet via the Company's website at
www.cbiolabs.com or at http://www.wsw.com/webcast/roth13/cald/.
Management will be available for investor meetings in New York on September
5-6, 2007.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries about programmed cell death to treat
cancer and protect normal tissues from exposure to radiation and other
stresses. The Company has strategic partnerships with the Cleveland Clinic
Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the
Armed Forces Research Radiobiology Institute. To learn more about
Cleveland BioLabs Inc., please visit the company's website at
http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. Our actual
results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Some of the
factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in our filings with the Securities and Exchange
Commission.